الفهرس 
Breast CancerOnly 14 pages are availabe for public view
 |  | from | 66 |  |  |
| | | from | 66 | | |
Abstract
Oral tamoxifen is a standard adjuvant therapy for women with breast cancer. It has been shown to improve disease free and overall survival in women with hormone receptor positive disease and the usual treatment period is 5 years Although it acts as an estrogen antagonist in breast tissue, it exerts weak estrogenic effect on the endometrium and hence is associated with various endometrial pathologies. The incidences of endometrial polyps, hyperplasia and endometrial cancer had been reported to be between (5 and 35%) (94.7–16%) and (0.8–5%) respectively
Design:. Study design This is a randomised controlled clinical trial that was commenced in Ain Shams University Oncology unit.
Subjects: Women with early stage breast cancer requiring postoperative adjuvant tamoxifen therapy are eligible upon completion of adjuvant chemotherapy and radiotherapy.
Sample size statement: group I (Control group): 60 patients on tamosifen treatment without LNG IUS system. group II (Study group): 60 patients on tamoxifen treatment with LNG IUS system
Results: In our results showed that LNG-IUS appear to prevent the development of benign endometrial lesion in breast cancer patient taking tamoxifen.